Martin Aringer
Overview
Explore the profile of Martin Aringer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
187
Citations
8590
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nielsen W, Kharouf F, Grajales C, Thayaparan A, Anderson M, Strand V, et al.
Semin Arthritis Rheum
. 2025 Mar;
72:152684.
PMID: 40056477
Objective: To identify candidate Systemic Lupus Erythematosus (SLE) domains from the literature for consideration towards the development of the SLE Core Outcome Set. Methods: This was a comprehensive scoping literature...
2.
Pfeil A, Fleck M, Aringer M, Baraliakos X, Ernst D, Haase I, et al.
Z Rheumatol
. 2025 Feb;
PMID: 40014094
The model advanced training regulations define the content of advanced training to achieve the qualification of medical specialist in all specialties and sub-specialties of medicine. As rheumatology is one of...
3.
Aringer M, Arnaud L, Furie R, Morand E, Peschken C, Hoi A, et al.
Lupus Sci Med
. 2025 Jan;
12(1).
PMID: 39855677
Objectives: Systemic lupus erythematosus (SLE) is a disease with heterogeneous treatment patterns largely based on organ involvement and disease severity. The SLE Prospective Observational Cohort Study (SPOCS) collected data worldwide...
4.
Aringer M, Distler O, Hoffmann-Vold A, Kuwana M, Prosch H, Volkmann E
RMD Open
. 2024 Dec;
10(4).
PMID: 39719300
Interstitial lung disease (ILD) associated with rheumatoid arthritis or with connective tissue diseases such as systemic sclerosis can be collectively named systemic autoimmune rheumatic disease-associated ILDs (SARD-ILDs) or rheumatic musculoskeletal...
5.
Pfeil A, Fleck M, Aringer M, Baraliakos X, Ernst D, Haase I, et al.
Z Rheumatol
. 2024 Dec;
84(1):59-67.
PMID: 39666002
The model advanced training regulations define the content of advanced training to achieve the qualification of medical specialist in internal medicine and rheumatology. There are currently no criteria for issuing...
6.
Nielsen W, Strand V, Simon L, Pinsker E, Bonilla D, Morand E, et al.
Semin Arthritis Rheum
. 2024 Aug;
68:152520.
PMID: 39106780
Background: Since the development of the OMERACT Systemic Lupus Erythematosus (SLE) Core Outcome Set (COS) in 1998, many new SLE domains have been identified and measures developed, creating a need...
7.
Mucke J, Aringer M
Z Rheumatol
. 2024 Jul;
83(6):431-438.
PMID: 39037547
The 2023 update of the EULAR recommendations for the management of systemic lupus erythematosus (SLE) faced several tasks: the newly approved medications anifrolumab and voclosporin as well as the additional...
8.
Hellmich B, Mucke J, Aringer M
Z Rheumatol
. 2024 Jul;
83(8):620-628.
PMID: 39017966
Head-to-head (H2H) studies enable the direct comparison of several alternative therapeutic approaches and thus provide the evidence-based foundation for the relative position of one treatment as compared to others for...
9.
Merrill J, Tanaka Y, DCruz D, Vila-Rivera K, Siri D, Zeng X, et al.
Arthritis Rheumatol
. 2024 Jun;
76(10):1518-1529.
PMID: 38923871
Objective: The 48-week, phase 2 SLEek study (NCT03978520) evaluated the efficacy and safety of upadacitinib (JAK inhibitor) and elsubrutinib (BTK inhibitor) alone or in combination (ABBV-599) in adults with moderately...
10.
Aringer M, Yazdany J
Lancet Rheumatol
. 2024 Jun;
6(8):e496-e498.
PMID: 38876130
No abstract available.